All articles by Gujjarlapudi Satish

  1. ESMO 2019: mCRC drug meets endpoints in Pfizer study

    Pfizer has reported positive data from the interim analysis of the Phase III BEACON CRC clinical study conducted to assess…
    Read More…

    1 Oct
  2. Nucala minimises exacerbations in eosinophilic asthma patients

    GlaxoSmithKline (GSK) has reported positive results from its study of Nucala (mepolizumab) in patients with severe eosinophilic asthma. Results were…
    Read More…

    1 Oct
  3. Astellas initiates trial to evaluate VMS therapy fezolinetant

    Astellas Pharma has initiated the SKYLIGHT 1 Phase III trial to evaluate fezolinetant for the treatment of moderate-to-severe vasomotor symptoms…
    Read More…

    6 Aug
  4. Lilly reports positive data from CONQUER study of Emgality

    Eli Lilly and Company has reported positive data from the Phase III CONQUER study of Emgality (galcanezumab-gnlm) in patients who…
    Read More…

    6 Aug
  5. Genentech reports positive data from cancer immunotherapy trial

    Roche Group member Genentech has reported positive results from the Phase III IMvigor130 combination trial of Tecentriq (Atezolizumab) and platinum-based…
    Read More…

    5 Aug
  6. Pfizer’s RESET trial of rivipansel fails to meet endpoints

    Pfizer’s Phase III Rivipansel (GMI-1070) Evaluating Safety, Efficacy and Time to Discharge (RESET) pivotal trial has failed to meet its…
    Read More…

    5 Aug
  7. Boehringer reports positive data from afatinib’s real-world study

    Boehringer Ingelheim has reported positive interim results from the real-world GioTag study of afatinib (Giotrif/Gilotrif) in EGFR Del19 and T790M…
    Read More…

    5 Aug
  8. New respiratory syncytial virus vaccine shows promise in Phase I trial

    An experimental vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID) to protect against respiratory syncytial virus…
    Read More…

    2 Aug
  9. AAV gene therapy shows positive results in Batten disease trial

    Amicus Therapeutics has announced interim data from a Phase I/II clinical trial of an AAV gene therapy for the treatment…
    Read More…

    2 Aug
  10. Novartis’ Kisqali improves survival in MONALEESA-3 participants

    Novartis has announced that the Phase III MONALEESA-3 study of Kisqali (ribociclib) has met its key secondary endpoint at interim…
    Read More…

    2 Aug
Close
Close
Close

Go Top